GT Apeiron Announces Development Candidate Nomination of Brain Penetrant PRMT5 Inhibitor, GTA182, for the Potential Treatment of MTAP-Deleted Solid Cancers
17 oct. 2023 07h00 HE
|
GT Apeiron LLC
GT Apeiron Therapeutics announces development candidate nomination of GTA182, a brain penetrant MTA-cooperative PRMT5 inhibitor
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
17 oct. 2023 04h00 HE
|
AKAMPION
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors ...
Kura Oncology Reports First Quarter 2023 Financial Results
10 mai 2023 16h03 HE
|
Kura Oncology, Inc.
– Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML...
Kura Oncology to Participate in JMP Securities Life Sciences Conference
09 mai 2023 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies
17 avr. 2023 07h30 HE
|
Kura Oncology, Inc.
– Preclinical data support the potential for FTIs in combination with KRASG12C inhibitors and TKIs to prevent or delay emergence of adaptive resistance – – Company preparing to initiate Phase 1...
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
11 avr. 2023 08h30 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight...
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
05 avr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
14 mars 2023 16h30 HE
|
Immuneering Corporation
Demonstrates ability to identify patient populations that may benefit from IMM-1-104 treatment Biomarker discovery and clinical translation supports patient selection in ongoing Phase 1/2a clinical...
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
05 mars 2023 18h30 HE
|
Immuneering Corporation
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid...
Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer
25 janv. 2023 21h15 HE
|
Cell BioEngines, Inc.
BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors,...